Consejo Superior De Investigaciones Cientificas

Universidad Autonoma De Madrid (Uam)

Neuropharma, S.a.

Instituto Biomar, S.a.

Noscira, S.a.

Universidad Autónoma De Madrid

Asd Therapeutics Partners, LLC

Ana Castro Morera

Mercedes Alonso Cascon

Ana Martinez Gil

Miguel Medina Padilla

Isabel Dorronsoro Diaz

Francisco Wandosell Jurado

Francisco Jose Moreno Munoz

Maria Concepcion Martin Perez

Paola Usan Egea

Esther Garcia Palomero

Ana Fuertes Huerta

Ana Martínez Gil

Maria Jose Perez Puerto

Laura Rubio Arrieta

Librada Maria Canedo Hernandez

Julia Perez Baz

Mercedes Alonso Cascón

Ana Gil Martinez

Maria Luisa Navarro Rico

Rosa Isabel Fernandez Chimeno

Ester Martin Aparicio

Jorge Sanchez Quesada

Francisco Romero Millan

Antonio Medarde Fernandez

Librada María Cañedo Hernández

Rosa Isabel Fernández Chimeno

Julia Pérez Baz

Jorge Sánchez Quesada

Esther García Palomero

Paola Usán Egea

Francisco Romero Millán

Ana Luisa Rodriguez Villanueva

Marta Vela Ruiz

Susana Herrero Santos

Ester MARTÍN Aparicio

María José PÉREZ Puerto

Mercedes Alonso CASCÓN

María Luisa Navarro Rico

Antonio FERNÁNDEZ Medarde

The invention relates to urea derivatives of formula (I) as inhibitors of glycogen synthase kinase 3&#x3b2;, GSK-3, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which GSK-3 is involved, such as Alzheimer's disease or non-insulin dependent diabetes mellitus. 

GSK-3 inhibitors

The present invention relates to a new family of [1,10]-phenantroline derivatives of formula (I), which are useful for the treatment or profilaxis of a neurodegenerative or haematological disease or condition, their use as a medicament, especially for treating a treatment neurodegenerative or haematological disease or condition, and a pharmaceutical composition comprising the compounds. 

[1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases

The present invention relates to the use of Collismycin and derivatives thereof as inhibitors of oxidative stress in cells and their use for the preparation of medicaments for the treatment of oxidative stress-induced diseases or conditions, especially neurodegenerative diseases, such as Alzheimer's Disease and Parkinson's Disease.

Use of collismycin and derivatives thereof as oxidative stress inhibitors

Compounds of general formula (I): where A, E, G, X, Y and the bond - - - take various meanings are of use in the preparation of a pharmaceutical formulation, for example in the treatment of a disease in which GSK-3 is involved, including Alzheimer's disease or the non-dependent insulin diabetes mellitus, or hyperproliferative disease such as cancer, displasias or metaplasias of tissue, psoriasis, arteriosclerosis or restenosis.

Enzyme inhibitors

Compounds of general formula (I):where A, E, G, X, Y and the bond - - - take various meanings are of use in the preparation of a pharmaceutical formulation, for example in the treatment of a disease in which GSK-3 is involved, including Alzheimer's disease or the non-dependent insulin diabetes mellitus, or hyperproliferative disease such as cancer, displasias or metaplasias of tissue, psoriasis, arteriosclerosis or restenosis.

Heterocyclic inhibitors of glycogen synthase kinase GSK-3

Growing community of inventors

Madrid, Spain

Ana Castro Morera